This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

65/100

✓ Peer-reviewed alzhub usefulness score 65 out of 100. Getting a diagnosis

Topic: Brain proteins, microglia and lab models

Results A total of 2571 participants were analyzed with UGOT, 1578 with Roche, and 304 with the C2N %p-tau217 ratio. In the UGOT cohort, the optimal cutoff improved diagnostic accuracy compared with the standard single cutoff, particularly in CKD and anemia (CKD: from 0.65; 95% CI, 0.57-0.72; to 0.83; 95% CI, 0.76-0.89; anemia: from 0.80; 95% CI, 0.76-0.84; to 0.86; 95% CI, 0.82-0.90), with consistent findings in the Roche cohort. In all biological subgroups, the double-cutoff strategy also increased accuracy relative to the single cutoff and reduced false classifications but yielded 12% to 39% intermediate results. These findings support biologically informed thresholds to improve diagnostic accuracy and cost efficiency when implementing plasma p-tau217.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Yun, J., Lee, J., Shin, D., Lee, E. H., Kim, J. P., Ham, H., et al. (2026). Plasma Phosphorylated Tau 217 Cutoffs for Amyloid Pathology and Kidney Function, Body Mass Index, and Anemia. JAMA neurology. https://doi.org/10.1001/jamaneurol.2025.5530

Vancouver

Yun J, Lee J, Shin D, Lee EH, Kim JP, Ham H, et al. Plasma Phosphorylated Tau 217 Cutoffs for Amyloid Pathology and Kidney Function, Body Mass Index, and Anemia. JAMA neurology. 2026. doi:10.1001/jamaneurol.2025.5530. PMID: 41627837.

BibTeX

@article{yun2026-41627837,
  author  = {Yun, Jihwan and Lee, Jungah and Shin, Daeun and Lee, Eun Hye and Kim, Jun Pyo and Ham, Hongki and Gu, Yuna and Chun, Min Young and others},
  title   = {{Plasma Phosphorylated Tau 217 Cutoffs for Amyloid Pathology and Kidney Function, Body Mass Index, and Anemia}},
  journal = {JAMA neurology},
  year    = {2026},
  doi     = {10.1001/jamaneurol.2025.5530},
  pmid    = {41627837},
  url     = {https://doi.org/10.1001/jamaneurol.2025.5530}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Results A total of 2571 participants were analyzed with UGOT, 1578 with Roche, and 304 with the C2N %p-tau217 ratio.
In the UGOT cohort, the optimal cutoff improved diagnostic accuracy compared with the standard single cutoff, particularly in CKD and anemia (CKD: from 0.65; 95% CI, 0.57-0.72; to 0.83; 95% CI, 0.76-0.89; anemia: from 0.80; 95% CI, 0.76-0.84; to 0.86; 95% CI, 0.82-0.90), with consistent findings in the Roche cohort.
In all biological subgroups, the double-cutoff strategy also increased accuracy relative to the single cutoff and reduced false classifications but yielded 12% to 39% intermediate results.
These findings support biologically informed thresholds to improve diagnostic accuracy and cost efficiency when implementing plasma p-tau217.

Why it matters

This study found that using two cutoff values instead of one for the blood marker p-tau217 improved diagnostic accuracy, especially in people with chronic kidney disease or anemia. The double-cutoff approach reduced false classifications but produced intermediate results in 12% to 39% of cases.

New to this subject? Start with our plain-English guide: Getting a diagnosis →

Study details

Study designcross-sectional
Participants2,571
Effect sizeDiagnostic accuracy for amyloid positivity in CKD: 0.65 (95% CI 0.57-0.72) with standard cut-off vs 0.83 (0.76-0.89) with subgroup-optimal cut-off
Evidence strengthModerate

Limitations

Cross-sectional Korean cohorts, so cut-offs may not transfer to other populations or laboratories; cost analysis used modelled assumptions; no longitudinal outcomes.

How this study scored 65/100

Published in a leading specialty journal, and it is a snapshot of people at one point in time. Scored zero for randomised / blinded because the record does not state it. We have no data on senior author's track record and free to read, so those were left out: it earned 61 of the 94 points we could judge it on, which is 65 out of 100.

Component	Points	Why
Journal tier	9 / 10	Tier 2 — leading specialty journal (JAMA neurology)
Journal's citation record	2 / 4	JAMA Neurology: journal h-index 235 (OpenAlex, 2026-10-29)
Study design	4 / 12	A snapshot of people at one point in time
Strength of evidence	3 / 5	Rated “moderate” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	5 / 5	2026 — within 1 year(s) of the newest study here
Sample size	3 / 4	2,571 participants
Effect reported	3 / 3	Effect reported with a statistic (interval, p-value, ratio or similar)
Studied in people	3 / 3	Studied in people (participant count stated)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	2 / 7	Cited 10 times (OpenAlex, 2026-10-10)
Citations per year	2 / 5	5.0 citations a year over 2 year(s) since 2026
Impact for its field and year	6 / 6	Cited 47.2× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	1 / 6	Cited by 2 other studies in this library
Still being cited	1 / 4	Cited 10 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	— / 4	OpenAlex's profile for last-listed author Beomsu Kim holds only 1 work(s), too few to judge a track record — left out of this score
Institution's track record	2 / 3	University College London: institution h-index 2,029 (OpenAlex)
Multi-centre collaboration	3 / 3	OpenAlex lists 34 institution(s) in 7 countries
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 41627837)
Free to read	— / 2	Access not recorded — left out of this score
Points	61 / 94	Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 61 of the 94 points we could judge it on is 65 out of 100.
Total	65 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

2 studies in the alzhub library list this one in their references.

Related studies in Getting a diagnosis

Also tagged “phosphorylated”

732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.

Similar studies

More on Getting a diagnosis

See all studies in Getting a diagnosis →